Wealth Enhancement Advisory Services
BPMC

Wealth Enhancement Advisory Services’s Blueprint Medicines BPMC Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,497
Closed -$449K – 3601
2025
Q2 		$449K Buy
3,497
+144
+4% +$15K ﹤0.01% 2308
2025
Q1 		$297K Buy
+3,353
New +$327K ﹤0.01% 2460

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wealth Enhancement Advisory Services's BPMC Position: Q3 2025 in Review

Wealth Enhancement Advisory Services sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 3,497 shares — an estimated $449K sold.

Wealth Enhancement Advisory Services first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $449K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Wealth Enhancement Advisory Services reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 3,497 Blueprint Medicines shares in Q3 2025, an estimated $449K.
  • Wealth Enhancement Advisory Services first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
  • Wealth Enhancement Advisory Services's Blueprint Medicines position peaked at $449K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2025, filed 29 Oct 2025.